title: [Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma - experience with the use of recombinant human thyrotropin].
abstract: Differentiated thyroid carcinoma is the most common endocrine malignancy with an excellent prognosis in the case of its early detection. Radioiodine 131I and thyroid hormones continue to be the pivotal drugs in treatment and follow-up for more than 50 years. The therapeutical and diagnostic options were recently expanded by the use of recombinant human thyrotropin (rhTSH). Our experience with the diagnostic administration of rhTSH confirms the outcomes of official trials and also indicates that the effect of rational therapy with 131I after rhTSH is similar to the outcome after standard regime using long-term thyroid hormone withdrawal.
authors: Klinika nuklearni mediciny a endokrinologie 2, Praha. marketa.mackova@fnmotol.cz
authors: M
authors: M
authors: Macková
authors: P
authors: P
authors: Vlček
mesh_terms: D002277:Carcinoma / Q000188:drug therapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D057073:Thyrotropin Alfa / Q000627:therapeutic use*
chemical_list: D007457:Iodine Radioisotopes; D057073:Thyrotropin Alfa